Is FDA More Conservative Than EMEA? FDA Says No; Investors Weigh In

Office of New Drugs director John Jenkins debates the perception that FDA approves fewer products than its regulatory counterparts in Europe. But some investors see troubling trends in data presented by the agency at the FDA/CMS Summit.